Stat
by Charles Piller
October 27, 2017
SAN FRANCISCO — A global pharma company is teaming up with federal research labs and academics in an ambitious effort to slash the time spent screening potential cancer drugs before they make it into the clinic for testing.
The new consortium — dubbed Accelerating Therapeutics for Opportunities in Medicine, or ATOM — unveiled its plans on Friday, after a nearly two years of planning. Its goal: To cut the preclinical development time from six years to one…
